id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0018,FDA,FDA-2007-D-0369,Publication of Guidances for Industry Describing Product-Specific Bioequivalence Recommendations,Notice,NAD-Notice of Availability of Data,2008-09-05T04:00:00Z,2008,9,2008-09-05T04:00:00Z,2008-12-05T04:59:59Z,2008-09-05T13:02:53Z,E8-20580,0,0,09000064806f2938
FDA-2007-D-0369-0019,FDA,FDA-2007-D-0369,See FDA-2007-D-0369-0015,Supporting & Related Material,GDL-Guidance,2008-09-05T04:00:00Z,2008,9,,,2024-11-12T04:19:29Z,,0,0,09000064806f2c6c
FDA-2007-D-0369-0015,FDA,FDA-2007-D-0369,Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Draft Guidance Document,Other,Guidance,2008-07-22T04:00:00Z,2008,7,2007-05-31T04:00:00Z,,2024-11-01T01:00:56Z,,0,0,09000064805f5666
FDA-2007-D-0369-0017,FDA,FDA-2007-D-0369,Medicis Pharmaceutical Corporation - Supplement,Other,Supplement (SUP),2008-07-22T04:00:00Z,2008,7,2007-05-30T04:00:00Z,2007-09-29T03:59:59Z,2015-03-13T04:13:40Z,,0,0,0900006480469825
FDA-2007-D-0369-0012,FDA,FDA-2007-D-0369,ASTS - Shipping Label,Supporting & Related Material,BKG-Background Material,2008-04-07T04:00:00Z,2008,4,,,2008-04-07T23:08:14Z,,0,0,0900006480468a0a
FDA-2007-D-0369-0011,FDA,FDA-2007-D-0369,Natco Pharma Limited to Center for Drug Evaluation and Research - Letter,Other,LET-Letter,2008-04-07T04:00:00Z,2008,4,2008-04-07T04:00:00Z,,2013-08-11T04:04:35Z,,0,0,090000648042bb8e